Toll-like receptor 2 pathway drives streptococcal cell wall-induced joint inflammation: critical role of myeloid differentiation factor 88.
Publication year
2003Source
Journal of Immunology, 171, iss. 11, (2003), pp. 6145-6153ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Rheumatology
Biochemistry (UMC)
Journal title
Journal of Immunology
Volume
vol. 171
Issue
iss. iss. 11
Page start
p. 6145
Page end
p. 6153
Subject
UMCN 1.4: Immunotherapy, gene therapy and transplantation; UMCN 4.2: Chronic inflammation and autoimmunity; UMCN 4.3: Tissue engineering and reconstructive surgeryAbstract
The IL-1R/Toll-like receptor (TLR) superfamily of receptors has a key role in innate immunity and inflammation. In this study, we report that streptococcal cell wall (SCW)-induced joint inflammation is predominantly dependent on TLR-2 signaling, since TLR-2-deficient mice were unable to develop either joint swelling or inhibition of cartilage matrix synthesis. Myeloid differentiation factor 88 (MyD88) is a Toll/IL-1R domain containing adaptor molecule known to have a central role in both IL-1R/IL-18R and TLR signaling. Mice deficient for MyD88 did not develop SCW-induced arthritis; both joint swelling and disturbance of cartilage chondrocyte anabolic function was completely abolished. Local levels of proinflammatory cytokines and chemokines in synovial tissue washouts were strongly reduced in MyD88-deficient mice. Histology confirmed the pivotal role of MyD88 in acute joint inflammation. TLR-2-deficient mice still allow influx of inflammatory cells into the joint cavity, although the number of cells was markedly reduced. No influx of inflammatory cells was seen in joints of MyD88-deficient mice. In addition, cartilage matrix proteoglycan loss was completely absent in MyD88 knockout mice. These findings clearly demonstrated that MyD88 is a key component in SCW-induced joint inflammation. Since agonists of the Toll-like pathway are abundantly involved in both septic and rheumatoid arthritis, targeting of MyD88 may be a novel therapy in inflammatory joint diseases.
This item appears in the following Collection(s)
- Academic publications [189120]
- Faculty of Medical Sciences [74529]
Upload full text
Use your RU credentials (u/z-number and password) tolog in with SURFconextto upload a file for processing by the repository team.